Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

European Commission grants orphan drug designation to sirolimus for sickle cell disease

Jan. 25, 2018

Imara initiates proof-of-concept phase II study of IMR-687 in sickle cell anemia

Jan. 23, 2018

New phase III trial explores use of BAX-111 in pediatric severe hereditary von Willebrand disease

Jan. 22, 2018

Spark's SPK-8011 given FDA orphan drug status for hemophilia A

Jan. 18, 2018

Darbepoetin alfa biosimilar JR-131 demonstrates equivalence in phase III study

Jan. 18, 2018

Endari now available in U.S. for sickle cell disease in adult and pediatric patients

Jan. 18, 2018

FDA accepts Ruconest sBLA for review

Jan. 17, 2018

Bioverativ conducts phase III trials with BIVV-009 in primary cold agglutinin disease

Jan. 17, 2018

European Commission approves Adynovi for hemophilia A

Jan. 15, 2018

FronThera US Pharmaceuticals presents novel hemoglobin modifier compounds

Jan. 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...